Libtayo shows increased survival benefit in hig... | Pluang
π Libtayo shows a 37% reduction in death risk for high-risk cutaneous squamous cell carcinoma patients compared to placebo after nearly four years of follow-up.
π The survival benefit persists even though 88% of placebo patients crossed over to Libtayo after disease recurrence, highlighting the drug's efficacy.
π¬ Libtayo improves disease-free survival regardless of minimal residual disease status at baseline, supporting its use as an adjuvant treatment post-surgery and radiation.
π₯ Findings presented at ESMO 2026 reinforce Libtayo's role as a transformative standard of care for high-risk CSCC patients.
π° Regeneron shares trade at USD 805.02 with a market cap of $82.88 billion and a dividend yield of 0.47%.
Bullish Signals
- Libtayo demonstrates a 37% reduction in death risk for high-risk cutaneous squamous cell carcinoma patients compared to placebo after nearly four years of follow-up.
- The drug improves disease-free survival regardless of minimal residual disease status at baseline, validating its efficacy as an adjuvant treatment post-surgery and radiation.
Full Analysis
Regeneron's Libtayo (cemiplimab) has demonstrated a significant overall survival benefit for patients with high-risk cutaneous squamous cell carcinoma (CSCC) following nearly four years of follow-up in the Phase 3 C-POST trial. The data, presented at ESMO 2026, reveal a 37% reduction in death risk compared to placebo, even though 88% of patients in the placebo group crossed over to Libtayo after their disease recurred.
Beyond overall survival, Libtayo also improves disease-free survival regardless of the patient's minimal residual disease status at baseline. These findings reinforce the drug's role as a transformative standard of care for high-risk CSCC and support its continued use as an adjuvant treatment following surgery and radiation therapy.